Project ImPACT Reduces Social Hyporesponsiveness and Translates to More Optimal Expressive Language Outcomes in Some Infants at Increased Likelihood of Autism.

J Autism Dev DisordJun 23, 2025 (epub)
Clinical ResearchPediatricsOpen access

Jennifer E Markfeld, Jacob I Feldman, Catherine T Bush et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial tested whether Project ImPACT, a caregiver-implemented naturalistic developmental behavioral intervention, could improve later expressive language in infant siblings of autistic children by reducing social hyporesponsiveness. Infants were assigned to 12 weeks of Project ImPACT or a control group. Social hyporesponsiveness was assessed immediately after intervention, and expressive language three months later. The intervention had an indirect association with expressive language outcomes through reduced social hyporesponsiveness, but this finding was limited to infants whose caregivers had high education levels at study entry.

Key findings

  • Project ImPACT indirectly influenced later expressive language through social hyporesponsiveness, but only among infants whose caregivers had high education levels at study entry.
  • The trial assigned 23 infants to Project ImPACT and 23 to a non-Project ImPACT control group.

Why it matters

The findings suggest that social responsiveness may be a pathway linking early caregiver-mediated intervention with later expressive language in infants at increased likelihood of autism. The education-related difference also indicates that intervention outcomes may vary across families, an important consideration when interpreting results and evaluating how early interventions work.

What to keep in mind

The reported indirect effect was limited to infants whose caregivers had high education levels at study entry, so the result may not generalize across caregiver education levels.

Source

Published in J Autism Dev Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.